Barclays 28th Annual Global Healthcare Conference March 10, 2026 11:30 AM EDTCompany ParticipantsRyan Cohlhepp - ...

Prophylactic use of K1 cream for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC). Background: To analyze post-neoadjuvant molecular events ...

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.

Bicara Therapeutics (NASDAQ:BCAX) outlined its clinical and development strategy for its lead bifunctional antibody program, ...

In January 2026, ALX Oncology announced topline data from the exploratory analysis conducted to identify biomarkers of response to the evorpacept/zanidatamab combination. These findings show that ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based ...

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...

This marks the first time a bispecific ADC has demonstrated a dual benefit in both PFS and OS within a phase 3 trial for TNBC ...